Protease For Acid Reflux Research Evidence 2026

---

Table of Contents

1. What Is Protease and Why Does It Matter for Acid Reflux?
2. Pepsin vs. Digestive Protease Supplements: Critical Differences
3. The 2024–2026 Research Landscape: What Studies Actually Say
4. Protease Benefits for Acid Reflux: Separating Hype from Evidence
5. Non-Acid Reflux, LPR, and the Pepsin Problem
6. Protease Inhibitors: The Emerging Clinical Angle
7. Protease Dosage for Acid Reflux: What the Evidence Suggests
8. Best Protease for Acid Reflux: How to Evaluate Supplements
9. Natural Protease Sources, Extracts, and Teas
10. Safety: Are Enzyme Supplements Safe for GERD?
11. Frequently Asked Questions
12. Bottom Line and Evidence Summary

---

Disclosure: This post contains affiliate links. We may earn a commission if you purchase through our links at no additional cost to you. All content is based on publicly available research and does not constitute medical advice.

---

What Is Protease and Why Does It Matter for Acid Reflux?

If you've spent any time researching digestive enzyme supplements, you've almost certainly encountered the term protease. It appears on the back panels of dozens of enzyme blends, often alongside lipase and amylase, marketed broadly as digestive support. But the relationship between protease acid reflux is far more nuanced — and scientifically interesting — than most supplement marketing lets on.

Proteases are enzymes that break down proteins by cleaving the peptide bonds that hold amino acid chains together. Your body produces several of them: pepsin in the stomach, trypsin and chymotrypsin in the small intestine, and various others throughout the digestive tract. Their primary job is protein digestion, but when they end up where they shouldn't be — like in the esophagus, throat, or lungs — they can trigger significant tissue damage and inflammation.

This is the crux of the modern research story around protease and acid reflux relief: the same class of enzyme that helps you digest a chicken breast can, under the wrong physiological conditions, become an agent of chronic injury.

To understand this topic properly, you need to distinguish between two very different questions:

1. Can supplemental digestive proteases (like bromelain, papain, or microbial proteases) help relieve acid reflux symptoms?
2. Does endogenous pepsin — your stomach's own protease — play a causative role in reflux disease, and can blocking it provide relief?

The research evidence in 2024–2026 is primarily advancing on the second question, not the first. Most consumer marketing focuses on the first. This gap between what the science is studying and what supplement companies are selling is exactly what this article will address.

---

---

Pepsin vs. Digestive Protease Supplements: Critical Differences

Before diving into the evidence, it is essential to establish a clear conceptual framework.

Pepsin: Your Stomach's Native Protease

Pepsin is the primary gastric protease, secreted by chief cells in the stomach lining as an inactive precursor called pepsinogen. At the low pH of the stomach (typically pH 1.5–3.5), pepsinogen is auto-activated into pepsin, which then breaks down dietary proteins. Pepsin is optimally active in the highly acidic stomach environment.

Here is where things get clinically important: pepsin doesn't disappear when stomach contents reflux upward. When gastric contents enter the esophagus, throat (laryngopharynx), or even the airways, pepsin travels with them. Once in these tissues, pepsin can be taken up by epithelial cells and stored. Even at near-neutral pH values like pH 7, pepsin has been shown to trigger proinflammatory and pro-oncogenic gene expression — without requiring acidic reactivation for all of its harmful effects.

This is fundamentally different from what happens when you take a protease supplement by mouth.

Supplemental Proteases: A Different Class

When people search for protease acid reflux supplement products, they are typically looking at enzyme blends containing one or more of the following:

• Bromelain — a cysteine protease extracted from pineapple
• Papain — derived from papaya
• Fungal proteases — often from Aspergillus oryzae or Aspergillus niger
• Serratiopeptidase — a bacterial-derived protease with claimed anti-inflammatory properties
• Pancreatic proteases — trypsin and chymotrypsin, derived from porcine or bovine pancreas

These are taken to help digest proteins in the small intestine, reduce bloating, or support overall digestive function. The proposed mechanism for reflux benefit is indirect: if proteins are digested more efficiently in the stomach and small intestine, gastric emptying may improve, and the stomach may generate less fermentation-related pressure that contributes to reflux episodes.

This is a plausible hypothesis. But as of 2026, there is limited high-quality human clinical trial data specifically supporting protease and acid reflux relief through enzyme supplementation in GERD patients.

The critical takeaway: The cutting-edge research in 2025–2026 is focused almost entirely on pepsin as a pathological agent and on drugs that inhibit pepsin — not on supplemental proteases as a treatment. Keeping this distinction clear will help you evaluate every claim you encounter in this space.

---

The 2024–2026 Research Landscape: What Studies Actually Say

The research on acid reflux with protease has shifted dramatically in the past two years. Here is a systematic summary of the published and ongoing work.

2024: Acid-Active Proteases and Protein Digestibility

A 2024 review published in Frontiers in Nutrition examined "Acid-active proteases to optimize dietary protein digestibility: a step towards sustainable nutrition." This research focused on proteases from the S53 family that remain active under acidic conditions, framing them as tools to improve how the body breaks down dietary proteins — particularly relevant for plant-based nutrition.

Relevance to reflux: Indirect at best. The authors were not studying GERD treatment. However, the paper raises an interesting point: if supplemental acid-active proteases could theoretically improve gastric protein breakdown, incomplete protein digestion causing prolonged gastric distension and acid secretion might be reduced. This remains speculative and untested in reflux-specific clinical populations.

Bottom line from this study: Acid-active proteases are promising for nutrition, but the paper does not provide evidence that taking them as supplements reduces reflux symptoms.

2025: Pepsin's Role in Reflux Pathogenesis — PMC Review

A significant 2025 review indexed on PubMed Central addresses the "Pathogenesis of pepsin-induced gastroesophageal reflux" — a comprehensive synthesis of the mechanisms by which pepsin contributes to GERD and extraesophageal reflux disease (EERD).

The review consolidates a growing body of evidence that pepsin-mediated injury is not purely acid-dependent. This is a paradigm-shifting concept for clinicians who have traditionally focused on acid suppression as the definitive treatment strategy. Non-acid reflux — defined as reflux events in which the pH of the refluxate is above 4 — has long been problematic for PPI therapy because PPIs work by suppressing acid production, not by neutralizing or immobilizing pepsin.

This review represents a foundational document for understanding protease acid reflux at the mechanistic level in 2025.

2025: Thesis Data on Pepsin and Fosamprenavir

A 2025 thesis summary provides some of the most granular experimental data currently available. Key findings reported include:

• Pepsin was common in disease specimens and absent in controls — confirming that elevated pepsin in laryngeal and esophageal tissues is a biomarker of reflux-related disease, not an incidental finding
• At pH 7, pepsin induced proinflammatory and cancer-associated gene expression — this is highly significant because pH 7 approximates the environment of the larynx and upper airways, meaning pepsin arriving in these tissues from reflux is biologically active even outside its classically defined optimal pH range
• Fosamprenavir prevented laryngeal inflammation in vivo — in animal models, the HIV protease inhibitor fosamprenavir (repurposed as a pepsin blocker) prevented pepsin-induced laryngeal tissue inflammation
• Fosamprenavir also prevented epithelial barrier disruption in vitro — suggesting a mechanism by which pepsin inhibition could preserve mucosal integrity in reflux-exposed tissues

This data is preclinical but represents the strongest mechanistic foundation for the pharmaceutical trials now underway.

2026: Landmark Study in Laryngoscope

In August 2026, the Medical College of Wisconsin's (MCW) Pepsin and Reflux Laboratory published "Modulation of Pepsin-Mediated Inflammatory Responses in Vocal Cord Epithelial Cells by Amprenavir" in Laryngoscope.

This study extends the fosamprenavir research directly into vocal cord tissue — highly relevant because laryngopharyngeal reflux (LPR) is one of the most undertreated and misdiagnosed reflux conditions, causing symptoms including chronic hoarseness, throat clearing, and post-nasal drip that do not always respond to PPIs.

The publication of this study in one of otolaryngology's leading journals marks a significant moment: the protease inhibitor approach to reflux is now being validated in peer-reviewed specialty literature, not just in basic science conference abstracts.

2026: Phase II Clinical Trial Commencing

Perhaps the most important development for the field: MCW's Pepsin and Reflux Laboratory has an estimated start date of September 2026 for a Phase II proof-of-concept clinical trial of fosamprenavir-sodium alginate in patients with PPI-refractory GERD.

The combination of fosamprenavir (pepsin inhibitor) with sodium alginate (a raft-forming agent that creates a physical barrier on top of stomach contents, reducing reflux) is a rational pharmaceutical strategy targeting pepsin rather than acid.

This is the first trial of its kind at the Phase II level. If results are positive, it will validate the hypothesis that protease inhibition — not just acid suppression — is a viable therapeutic target in GERD.

What this means for consumers today: No approved pepsin-inhibiting drug exists yet. The clinical trial is beginning in September 2026 and results will not be available for some time. Consumer enzyme supplements are not pepsin inhibitors in this pharmacological sense.

---

Protease Benefits for Acid Reflux: Separating Hype from Evidence

Given the research above, what can we honestly say about protease benefits acid reflux claims you see in supplement marketing?

Claim 1: "Digestive Enzymes Help Your Stomach Empty Faster, Reducing Reflux"

Plausibility: Moderate. Evidence: Weak to moderate.

Impaired gastric emptying (gastroparesis) is a recognized contributor to GERD. If the stomach empties more slowly, there is more opportunity for gastric contents to reflux. Some studies suggest that digestive enzyme supplementation — particularly in people with exocrine pancreatic insufficiency or age-related enzyme decline — can support gastric function.

However, most people with GERD do not have clinically significant enzyme deficiency. For the average GERD patient, there is no robust clinical trial evidence that adding supplemental proteases meaningfully improves gastric emptying or reduces reflux episodes.

Claim 2: "Bromelain and Papain Help address inflammation in the Esophagus"

Plausibility: Low to moderate. Evidence: Very weak for GERD specifically.

Both bromelain and papain have demonstrated anti-inflammatory properties in other contexts (post-surgical swelling, sports injuries, sinusitis). Bromelain in particular has a reasonable anti-inflammatory evidence base. However, esophageal inflammation in GERD is largely driven by acid exposure and, increasingly, by pepsin-mediated pathways. Whether orally administered bromelain reaches esophageal tissue in concentrations sufficient to modulate inflammation is not established.

Claim 3: "Proteases Help Break Down Proteins That Might Ferment and Cause Gas and Pressure"

Plausibility: Moderate. Evidence: Indirect.

This is probably the most mechanistically defensible claim. Incomplete protein digestion can contribute to small intestinal bacterial overgrowth (SIBO) and intestinal fermentation, both of which increase intraabdominal pressure and can worsen reflux. Improving upstream protein digestion with supplemental proteases might reduce this downstream pressure. But this remains a multi-step hypothesis without direct clinical trial confirmation in GERD populations.

What the Evidence Actually Supports

The strongest evidence in 2025–2026 does not support taking protease supplements to relieve acid reflux as a primary strategy. Instead, it supports:

1. Targeting pepsin as a pathological agent through pharmaceutical inhibitors (under trial)
2. Using alginate-based barriers to reduce reflux exposure of the esophagus and larynx
3. Recognizing that non-acid reflux is a real clinical problem not fully addressed by acid suppression alone

---

---

Non-Acid Reflux, LPR, and the Pepsin Problem

Understanding the difference between GERD, LPR, and non-acid reflux is essential context for interpreting protease-related research.

GERD (Gastroesophageal Reflux Disease)

GERD is the most common reflux diagnosis, defined by the retrograde flow of gastric contents into the esophagus causing symptoms (heartburn, regurgitation) or complications. The standard treatment is proton pump inhibitors (PPIs), which reduce acid secretion. However, up to 40% of GERD patients have persistent symptoms on PPIs — the so-called PPI-refractory population that the MCW Phase II trial is specifically targeting.

LPR (Laryngopharyngeal Reflux)

LPR occurs when gastric contents reach the larynx, pharynx, and even the airways. Classic symptoms include hoarseness, chronic throat clearing, globus sensation (feeling of a lump in the throat), and chronic cough. Many LPR patients do not experience classic heartburn, making diagnosis challenging.

PPIs are frequently prescribed for LPR but evidence for their efficacy is mixed, particularly for non-acid LPR. This is where pepsin's pH-independent activity becomes most clinically significant.

Non-Acid Reflux: Why PPIs Aren't Enough

When reflux occurs with a pH above 4 — classified as non-acid or weakly acidic reflux — traditional acid suppression therapy provides limited protection. Yet pepsin is still present in this weakly acidic or near-neutral refluxate. As the 2025 thesis data shows, pepsin at pH 7 can still induce proinflammatory and pro-oncogenic gene expression in laryngeal epithelial cells.

This creates a significant therapeutic gap: patients with predominantly non-acid reflux, or with LPR driven by pepsin-mediated injury rather than pure acid, may not respond to PPIs precisely because the damaging agent isn't acid — it's the protease.

The Clinical Significance for Consumers

If you have been diagnosed with LPR or have reflux symptoms that persist despite PPI therapy, the emerging pepsin-inhibition research is directly relevant to your situation. It does not yet translate to available consumer products, but it does suggest that targeting protease activity — not just acid — is a legitimate and scientifically grounded therapeutic direction.

---

Protease Inhibitors: The Emerging Clinical Angle

The phrase "protease inhibitor" most commonly appears in the context of HIV antiretroviral therapy. Fosamprenavir, the drug being repurposed in the MCW reflux trials, is an HIV protease inhibitor. This might seem like an unusual connection, but it is mechanistically elegant.

HIV protease inhibitors work by blocking the active site of viral proteases — the enzymes HIV uses to assemble new viral particles. Pepsin, like HIV protease, is an aspartyl protease (it uses aspartate residues at its active site for catalysis). Fosamprenavir and related compounds can bind to and inhibit aspartyl proteases broadly, including pepsin.

Why Fosamprenavir?

The MCW research team identified fosamprenavir as a candidate pepsin inhibitor through screening of known protease inhibitors. The 2025 thesis data confirmed its efficacy in cell culture and animal models:

• Prevented laryngeal inflammation in vivo
• Preserved epithelial barrier integrity in vitro
• Modulated inflammatory gene expression induced by pepsin at near-neutral pH

The sodium alginate component of the drug combination being tested adds a physical barrier mechanism: alginate forms a gel "raft" on the surface of gastric contents, reducing the amount of material available to reflux upward.

What This Means for the "Protease Acid Reflux Supplement" Market

Currently, no consumer supplement contains a validated pepsin inhibitor. Some products marketed as "digestive enzyme inhibitors" or "reflux enzyme blockers" exist in the market, but they do not have clinical trial evidence at the level of the MCW work.

The distinction is critical:

• Taking digestive protease enzymes ≠ inhibiting pepsin
• In fact, taking additional proteases could theoretically be contraindicated in someone whose reflux is primarily driven by excessive pepsin exposure in the esophagus and larynx, though this has not been studied directly

The pharmaceutical approach (pepsin inhibition) and the supplement approach (protease supplementation) are operating in nearly opposite directions in terms of mechanism.

---

Protease Dosage for Acid Reflux: What the Evidence Suggests

When consumers ask about protease dosage acid reflux, they are typically asking about supplemental enzyme doses from products like digestive enzyme blends. Here is an honest review of what the evidence supports.

Enzyme Activity Units: Understanding the Labels

Supplemental proteases are measured in activity units, not milligrams. Common unit systems include:

• HUT (Hemoglobin Units on a Tyrosine basis) — commonly used for fungal proteases
• USP units — used for pancreatic proteases
• GDU (Gelatin Digesting Units) or MCU (Milk Clotting Units) — sometimes used for bromelain
• FCC units — Food Chemicals Codex standard

A typical broad-spectrum digestive enzyme supplement might contain 50,000–100,000 HUT of protease activity per serving. Higher-strength formulas can reach 200,000–300,000 HUT.

Dosage Ranges in Context

For general digestive support, most enzyme manufacturers recommend taking 1–2 capsules with each meal. This is a functional guideline based on supporting protein digestion in the stomach and small intestine, not a therapeutic dose established in reflux clinical trials.

For people with exocrine pancreatic insufficiency (EPI): Prescription pancreatic enzyme replacement therapy (PERT) involves doses of 25,000–80,000 lipase units per meal (with proportional protease content), and these doses are established through clinical trials. GERD is a different condition.

What Dosage Should You Use If You Want to Try Protease Supplements for Reflux?

Given the absence of reflux-specific clinical trial data for supplemental proteases, the honest answer is: no evidence-based dosage exists for this indication. If you choose to try a digestive enzyme supplement as part of a broader digestive support strategy, following manufacturer instructions (typically 1 capsule with meals) is a reasonable starting point, with the understanding that this is not supported by high-quality clinical evidence for GERD specifically.

Work with a healthcare provider, particularly if you are on PPIs or other GERD medications, before adding any enzyme supplement.

---

Best Protease for Acid Reflux: How to Evaluate Supplements

When people search for the best protease for acid reflux, they deserve an honest evaluative framework rather than a list of sponsored recommendations. Here is how to think critically about products in this category.

Evaluation Criteria

1. Enzyme strain and source transparency The best products will identify the specific protease strains used (e.g., "Protease from Aspergillus oryzae") rather than using vague umbrella terms. This matters because different proteases have different pH optima and substrate specificities.

2. pH stability profile If a protease supplement is intended to work in the stomach (pH 1.5–3.5), it needs to contain acid-stable proteases. Many standard fungal proteases from Aspergillus species have reasonable acid stability. However, if the goal is small intestinal support, proteases with higher pH optima are more appropriate and should ideally be enteric-coated.

3. Third-party testing Enzyme activity degrades over time and with improper storage. Look for products with third-party verification of enzyme activity (NSF, USP, or Informed Sport certification, or independent certificate of analysis).

4. Absence of reflux-triggering excipients Check inactive ingredients. Some enzyme capsules contain citric acid, peppermint, or other flavoring agents that can relax the lower esophageal sphincter and worsen reflux.

5. Realistic marketing claims Be skeptical of any product claiming to be a "natural cure" for GERD or claiming to "eliminate acid reflux." As reviewed above, the evidence does not support these claims for supplemental proteases.

Categories Worth Considering

• Broad-spectrum digestive enzymes with protease, lipase, and amylase: reasonable for general digestive support; not proven for GERD specifically
• Bromelain-based formulas: some anti-inflammatory evidence, though not GERD-specific
• Betaine HCl + pepsin products: paradoxically, these contain pepsin — these are typically used for low stomach acid, not excess acid, and could theoretically worsen LPR symptoms in susceptible individuals

---

---

Natural Protease Sources, Extracts, and Teas

Natural Protease Acid Reflux Options in Food

When people search for natural protease acid reflux remedies, they are often looking for dietary approaches. Several foods are rich in proteolytic enzymes:

Pineapple (Bromelain) Fresh pineapple contains bromelain, which is active in the stomach. Some people report digestive benefit from eating fresh pineapple with meals. However, canned pineapple has denatured bromelain (heat processing destroys enzyme activity). Pineapple is also acidic, which can exacerbate heartburn symptoms in some reflux patients.

Papaya (Papain) Ripe papaya contains papain. As with pineapple, this may support protein digestion. Green, unripe papaya contains higher papain concentrations. Papaya extract is a common ingredient in enzyme supplements.

Ginger Ginger contains zingibain, a cysteine protease. Ginger also has well-documented prokinetic effects — it speeds gastric emptying — which may be relevant for reflux driven by delayed gastric emptying. Ginger tea is a commonly used home remedy for nausea and digestive discomfort.

Fermented Foods Kimchi, miso, kefir, and certain aged cheeses contain proteolytic enzymes from bacterial and fungal fermentation. These are generally supportive of overall digestive health.

Protease Extract Acid Reflux: What to Know

When searching for protease extract acid reflux products, you will encounter concentrated extracts of bromelain, papain, or microbial proteases standardized to enzyme activity units. These offer higher and more consistent enzyme delivery than whole foods. As noted above, there is no clinical trial evidence specific to reflux, but these extracts have a reasonable digestive support rationale.

Protease Tea Acid Reflux: The Evidence

Protease tea acid reflux is a niche search term that typically refers to herbal teas purported to stimulate digestive enzyme production or contain plant-based enzymes. The evidence here is largely anecdotal.

Ginger tea has the strongest scientific support for digestive benefits related to reflux, primarily through its prokinetic mechanism rather than direct enzyme action.

Licorice root tea (DGL) is worth mentioning in this context. Deglycyrrhizinated licorice (DGL) has some clinical evidence for supporting the gastric mucosal barrier and may reduce heartburn symptoms. It works through a different mechanism (mucosal protection, not enzyme activity) but is often discussed alongside digestive enzyme remedies.

Slippery elm tea creates a mucilaginous coating that some people find soothing for esophageal irritation, though formal clinical evidence is limited.

Important note on green tea: Some people consume green tea hoping for anti-inflammatory benefits. However, green tea is acidic (pH approximately 7–10 for the beverage) and contains caffeine, both of which can worsen reflux symptoms in susceptible individuals.

---

Safety: Are Enzyme Supplements Safe for GERD?

One of the most common reader questions is whether enzyme supplements are safe for GERD. The answer depends on several factors.

Generally Recognized as Safe (GRAS) Status

Most enzyme ingredients in commercial supplements — bromelain, papain, fungal proteases from Aspergillus species — have a long history of use and are generally considered safe at recommended doses for most people.

Specific GERD-Related Concerns

1. Betaine HCl + Pepsin products These supplements are designed to increase stomach acid in people with hypochlorhydria (low stomach acid, common in older adults or those with H. pylori infection). They should be used with extreme caution or avoided by people with active GERD, esophagitis, or peptic ulcers. Adding pepsin is particularly contraindicated given the emerging evidence on pepsin-mediated tissue injury.

2. Pineapple-derived products Bromelain in concentrated supplement form can cause gastrointestinal irritation in some people. Fresh pineapple's acidity may trigger heartburn.

3. Interactions with PPIs PPIs raise gastric pH, which may affect the activity of some acid-dependent supplemental enzymes. This is a theoretical concern rather than a documented clinical problem, but worth considering.

4. Allergies People with allergies to pineapple, papaya, latex (due to cross-reactivity), or specific mold species should avoid related enzyme products.

When to Consult a Doctor

• If you have been diagnosed with erosive esophagitis or Barrett's esophagus
• If you are on PPI therapy for established GERD
• If you are pregnant or breastfeeding
• If you have a history of peptic ulcer disease
• If your symptoms include dysphagia (difficulty swallowing), unintended weight loss, or bloody stools — these require immediate medical evaluation

---

Frequently Asked Questions

Does protease help acid reflux or heartburn?

Supplemental digestive proteases have not been proven in clinical trials to directly reduce acid reflux or heartburn. They may support protein digestion, which could indirectly reduce gastric distension and pressure that contributes to reflux in some people. However, the strongest current evidence involves pepsin — the stomach's own protease — as a causative agent in reflux-related tissue injury, and pharmaceutical research is focused on inhibiting pepsin, not supplementing with more protease.

Is pepsin different from digestive protease supplements?

Yes, significantly. Pepsin is your stomach's endogenous protease, optimally active at very low pH but capable of inducing inflammation and pro-oncogenic gene expression even at neutral pH (as shown in 2025 research). Supplemental digestive proteases (bromelain, papain, fungal proteases) are exogenous enzymes taken to support food digestion and have different biochemical properties and mechanisms. They are not equivalent to, nor substitutes for, pharmaceutical pepsin inhibitors.

Can protease inhibitors reduce reflux-related throat symptoms?

Based on the 2025–2026 research from MCW's Pepsin and Reflux Laboratory, fosamprenavir (a pharmaceutical protease inhibitor) shows promise for reducing pepsin-mediated laryngeal inflammation in preclinical models. A Phase II clinical trial beginning in September 2026 will provide the first controlled human data. Consumer-available "protease inhibitor" supplements do not have this level of evidence.

Is there evidence that protease affects non-acid reflux?

Yes. The pepsin-centered research is especially relevant to non-acid reflux, where acid suppression with PPIs is insufficient because the damaging agent is pepsin, not acid. Pepsin's ability to induce tissue injury at pH 7 makes it relevant to all reflux types, including weakly acidic and non-acid reflux.

Are enzyme supplements safe for GERD?

Most standard digestive enzyme supplements (bromelain, papain, broad-spectrum fungal enzymes) are generally safe for most adults at recommended doses. However, betaine HCl with pepsin products should be avoided in GERD patients. Always check with your doctor before adding supplements if you are on PPIs or have diagnosed esophagitis.

What is the difference between GERD, LPR, and pepsin-related reflux?

GERD involves gastric contents refluxing into the esophagus. LPR involves refluxate reaching the larynx and pharynx. Pepsin-related reflux refers specifically to injury caused by the protease pepsin in refluxed material, and is relevant to both GERD and LPR. Many LPR cases may be driven primarily by pepsin rather than acid, explaining why PPIs often fail for this condition.

Are there any human trials for protease-based reflux treatments?

As of 2026, the MCW Phase II trial of fosamprenavir-sodium alginate for PPI-refractory GERD has an estimated start date of September 2026. This is the first known Phase II human trial specifically targeting pepsin inhibition for reflux. Results will not be available for at least 1–2 years after commencement.

Does PPI treatment affect pepsin-related symptoms?

PPIs reduce acid secretion, which means gastric contents are less acidic when reflux occurs. However, pepsin is still present in the stomach and in refluxed material even when pH is elevated by PPIs. At near-neutral pH, pepsin is less proteolytically active by classical measures, but research shows it can still induce significant inflammatory signaling. This is one reason why PPI-refractory patients may have ongoing symptoms — the pepsin problem persists even when acid is suppressed.

---

---

Bottom Line and Evidence Summary

Let's return to the central question: what does the 2024–2026 research evidence actually say about protease for acid reflux?

What the Evidence Strongly Supports

1. Pepsin is a pathologically significant protease in reflux disease. Multiple lines of evidence from 2025–2026, including PMC-indexed reviews, a detailed thesis study, and a peer-reviewed Laryngoscope publication, confirm that pepsin causes tissue injury in the esophagus, larynx, and airways — and that this injury occurs even at near-neutral pH, independent of acid.

1. Pepsin inhibition is an emerging and scientifically legitimate therapeutic target. The September 2026 Phase II clinical trial of fosamprenavir-sodium alginate represents the field's transition from preclinical promise to clinical testing.

1. Non-acid reflux is a real, under-treated problem. For patients who don't respond to PPIs, pepsin-mediated pathology may be a key explanation, and this has implications for treatment strategy.

What the Evidence Does Not Strongly Support

1. Taking supplemental proteases (bromelain, papain, fungal enzymes) as a primary treatment for GERD or LPR. There are no high-quality clinical trials supporting this indication.

1. Protease teas or extracts as clinically meaningful reflux treatments. Some may offer general digestive support or soothing effects, but should not be positioned as evidence-based reflux therapy.

1. High protease enzyme blends for people with LPR or pepsin-driven reflux. The logic of adding more protease when pepsin-mediated injury is the problem is mechanistically questionable.

Practical Guidance for Readers

| If You Have... | Evidence-Based Approach | |---|---| | Classic GERD (heartburn, regurgitation) | Work with a doctor; PPIs are first-line; enzyme supplements may support digestion but won't replace acid management | | LPR (hoarseness, throat clearing, non-heartburn symptoms) | PPI evidence is mixed; pepsin research suggests this may be a protease-mediated problem; discuss with an ENT or gastroenterologist | | PPI-refractory GERD | You may be a candidate for the emerging pepsin-inhibitor trials; discuss with a specialist; alginate-based antacids (available OTC) may provide additional barrier protection | | Interest in natural digestive support | Ginger, papaya, pineapple, and fermented foods have general digestive support evidence; avoid anything that triggers your symptoms; be skeptical of cure-level claims |

Looking Ahead

The September 2026 Phase II trial of fosamprenavir-sodium alginate is the most important development in protease acid reflux research in years. If positive results emerge, they could fundamentally reshape how reflux — particularly PPI-refractory GERD and LPR — is treated, moving from pure acid suppression toward enzyme-targeted therapy.

For consumers right now, the honest conclusion is this: supplemental proteases may offer modest digestive support, but they are not the protease story that matters most in 2026. That story is about inhibiting the protease that's causing harm — pepsin — not adding more enzymes to an already enzyme-complicated system.

---

This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting any supplement or changing your treatment plan for GERD or related conditions.

---

Sources Referenced:

• MCW Pepsin and Reflux Laboratory (mcw.edu)
• PMC: Pathogenesis of pepsin-induced gastroesophageal reflux (PMC11880273)
• Dietary Supplement DB: Pepsin Complete Guide 2026
• Frontiers in Nutrition 2024: Acid-active proteases and protein digestibility
• MCW 2026: Fosamprenavir-sodium alginate Phase II trial (estimated start September 2026)
• Laryngoscope August 2026: Modulation of Pepsin-Mediated Inflammatory Responses in Vocal Cord Epithelial Cells by Amprenavir
• 2025 thesis data on pepsin in GERD specimens, fosamprenavir efficacy in preclinical models